Close Menu

NEW YORK (GenomeWeb) – Becton Dickinson reported today that its fiscal second quarter revenues decreased approximately 1 percent year over year.

On a comparable, currency-neutral basis, Q2 revenues increased more than 3 percent, BD said.

For the three months ended March 31, BD posted revenues of $4.20 billion compared to $4.22 billion in the year-ago quarter and below the analysts' average estimate of $4.24 billion.

BD's Medical segment revenues were up less than 1 percent to $2.18 billion from $2.17 billion a year ago. 

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The former commissioner of the FDA has returned to the venture capital firm New Enterprise Associates as a special partner on the healthcare investment team.

Astronauts have edited yeast genes on the International Space Station in an experiment designed to show how cells repair themselves in space.

Emory University has found that two of its researchers failed to divulge they had received funds from China, according to the Atlanta Journal-Constitution.

In Science this week: influence of the nuclear genome on human mitochondrial DNA, and more.

Sponsored by

This webinar will overview the potential for liquid biopsy approaches to monitor therapy resistance in lung cancer.

Sponsored by

This webinar will discuss background and clinical genomics of NTRK fusion detection in cancer. NTRK fusions are the focus of new therapeutic options, but clonal and subclonal lesions are notoriously difficult to detect. 

Sponsored by

This webinar will share the results of comparisons of commercially available nucleic acid amplification tests for use in routine screening of pregnant women for Group B Streptococcus (GBS).